Dr. Alexandre Bolze is a principal scientist and principal investigator at Helix Inc., a California-based biotech company. Helix works with health systems across North America (16 health systems as of January 2025) to integrate genomics into healthcare. His research interests span both clinical and basic research. In his clinical research, Dr. Bolze focuses on assessing the clinical impact of having pathogenic variants in CDC Tier 1 genes within the general population. He also works on expanding screening panels for population screening by combining rare variants and polygenic risk scores, and investigates the genetics of disease resistance. Dr. Bolze's basic research is centered on understanding the genetics of immune responses following vaccination, including rare adverse events like myocarditis. He leads an international consortium dedicated to this research.